Literature DB >> 20191334

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era.

Davide Bedognetti, Gabriele Zoppoli, Mario Roberto Sertoli, Elisa Zanardi, Pietro Blandini, Lorenzo Uccellini, Francesco Boccardo, Giovanni Battista Andreoli, Riccardo Ghio, Omar Racchi, Manlio Ferrarini, Andrea De Maria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20191334     DOI： 10.1007/s12185-010-0522-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  12 in total

Review 1.  A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.

Authors:  Arturo Molina
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

2.  From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients.

Authors:  Gabriele Zoppoli; Zoppoli Gabriele; Bianca Bruzzone; Bruzzone Bianca; Patrizia Caligiuri; Caligiuri Patrizia; Antonino Picciotto; Picciotto Antonino; Enrico Balleari; Balleari Enrico; Andrea Bruzzone; Bruzzone Andrea; Giancarlo Icardi; Icardi Giancarlo; Riccardo Ghio; Ghio Riccardo
Journal:  Br J Haematol       Date:  2008-12-12       Impact factor: 6.998

3.  Risk of HBV liver disease in isolated antiHbc patients receiving immuno-chemotherapy for non Hodgkin lymphoma.

Authors:  C Targhetta; M G Cabras; E Angelucci
Journal:  Haematologica       Date:  2008-11       Impact factor: 9.941

4.  Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier.

Authors:  N Fukushima; T Mizuta; M Tanaka; M Yokoo; M Ide; T Hisatomi; N Kuwahara; R Tomimasu; N Tsuneyoshi; N Funai; E Sueoka
Journal:  Ann Oncol       Date:  2009-06-26       Impact factor: 32.976

Review 5.  Prophylaxis and treatment of hepatitis B in immunocompromised patients.

Authors:  A Marzano; E Angelucci; P Andreone; M Brunetto; R Bruno; P Burra; P Caraceni; B Daniele; V Di Marco; F Fabrizi; S Fagiuoli; P Grossi; P Lampertico; R Meliconi; A Mangia; M Puoti; G Raimondo; A Smedile
Journal:  Dig Liver Dis       Date:  2007-03-26       Impact factor: 4.088

6.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Authors:  Winnie Yeo; Tung C Chan; Nancy W Y Leung; Wai Y Lam; Frankie K F Mo; Miu Ting Chu; Henry L Y Chan; Edwin P Hui; Kenny I K Lei; Tony S K Mok; Paul K S Chan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Rituximab treatment results in impaired secondary humoral immune responsiveness.

Authors:  Lizet E van der Kolk; Joke W Baars; Martin H Prins; Marinus H J van Oers
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.

Authors:  Sung-Nan Pei; Chien-Hung Chen; Chuan-Mo Lee; Ming-Chung Wang; Ming-Chun Ma; Tsung-Hui Hu; Ching-Yuan Kuo
Journal:  Ann Hematol       Date:  2009-08-21       Impact factor: 3.673

9.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

Review 10.  Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Masashi Mizokami; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2009-06-23       Impact factor: 2.490
View more
  2 in total

Review 1.  Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Ryuzo Ueda; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2010-10-06       Impact factor: 7.527

2.  Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Authors:  Davide Bedognetti; Gabriele Zoppoli; Carlotta Massucco; Elisa Zanardi; Simonetta Zupo; Andrea Bruzzone; Mario Roberto Sertoli; Enrico Balleari; Omar Racchi; Marco Messina; Graziano Caltabiano; Giancarlo Icardi; Paolo Durando; Francesco M Marincola; Francesco Boccardo; Manlio Ferrarini; Filippo Ansaldi; Andrea De Maria
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.